PTPRS and chromophobe renal cell carcinoma: Compared to ccRCC (Fig. 2) BAP1, CHEK2, IRS1, PBRM1, SETD2, TERT, and VHL in evRCC patients, PAX8, CDKN2A, CDKN2B, FANCC, FGFR4, PIK3C, PTPRS, SMARCB1, TERT in pRCC ASXL2, BRCA1, CDH1, CDKN2A, CDKN2B, CDKN2C, DNMT1, and EP300 mutations in chRCC patients were mainly found.